Search results for "From ACP Internist"
Rosuvastatin, atorvastatin compared on effectiveness, safety in industry-funded trial
Analysis of a randomized trial in South Korea found that patients randomized to rosuvastatin developed type 2 diabetes requiring medication at a rate of 7.2%, compared to 5.3% among those given atorvastatin.
https://diabetes.acponline.org/archives/2023/11/10/8.htm
10 Nov 2023
‘Night owls' more likely to have unhealthy lifestyles, higher diabetes risk
In a retrospective cohort study, people with an evening chronotype were more likely to smoke, sleep poorly, and be physically inactive and had a 72% higher risk for diabetes than those with a morning chronotype.
https://diabetes.acponline.org/archives/2023/10/13/11.htm
13 Oct 2023
Higher aspirin dose no more effective for CV prevention in high-risk patients with diabetes
A subgroup analysis of a randomized trial found that patients with diabetes and atherosclerotic cardiovascular (CV) disease had similar outcomes whether they took 81 mg or 325 mg of aspirin daily.
https://diabetes.acponline.org/archives/2023/10/13/10.htm
13 Oct 2023
Almost 4 in 10 with type 1 diabetes were diagnosed in adulthood
Peak diagnosis age was approximately 15 years, and the median age of diagnosis was 24 years, but 37% of adults with type 1 diabetes reported having been diagnosed after age 30 years in a recent study.
https://diabetes.acponline.org/archives/2023/10/13/9.htm
13 Oct 2023
SGLT-2 inhibitors reduced gout flares in patients with diabetes, gout
New users of sodium-glucose cotransporter-2 (SGLT-2) inhibitors had about half the risk of an ED visit or hospitalization for a gout flare as matched patients taking dipeptidyl peptidase-4 inhibitors, a cohort analysis found.
https://diabetes.acponline.org/archives/2023/08/11/7.htm
11 Aug 2023
Nonsugar sweeteners should not be used for weight loss, WHO guideline states
The World Health Organization (WHO) cited a lack of evidence suggesting that short-term use of nonsugar sweeteners affected body weight or other measures of adiposity, as well as possible long-term undesirable effects on noncommunicable diseases and death.
https://diabetes.acponline.org/archives/2023/06/09/7.htm
9 Jun 2023
Large review compares benefits, harms of drugs to treat type 2 diabetes
High-certainty evidence indicated that sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists reduce all-cause death, while finerenone probably also reduced mortality based on moderate-certainty evidence.
https://diabetes.acponline.org/archives/2023/05/12/6.htm
12 May 2023
Nocturnal hypoglycemia underdiagnosed in older patients on insulin for type 2 diabetes
An industry-funded study of patients age 75 years and older who were taking insulin for type 2 diabetes found that almost two-thirds (65.2%) experienced nocturnal hypoglycemia during a 28-day study period.
https://diabetes.acponline.org/archives/2023/04/14/6.htm
14 Apr 2023
Overweight, obesity poorly managed in type 1 diabetes
While U.S. adults with type 1 diabetes have rates of overweight and obesity virtually identical to those in the general adult population, only about 50% received lifestyle recommendations for weight management from clinicians or tried lifestyle modifications.
https://diabetes.acponline.org/archives/2023/03/10/9.htm
10 Mar 2023
Getting to know GLP-1 receptor agonists
The latest Pearls from I.M. Peers offers advice on prescribing glucagon-like peptide-1 (GLP-1) receptor agonists for patients with diabetes.
https://diabetes.acponline.org/archives/2023/03/10/8.htm
10 Mar 2023